Allianz SE Makes New $151,000 Investment in Moderna, Inc. (NASDAQ:MRNA)

Allianz SE acquired a new stake in shares of Moderna, Inc. (NASDAQ:MRNA) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 3,842 shares of the company’s stock, valued at approximately $151,000.

A number of other hedge funds have also made changes to their positions in the stock. Wilmington Savings Fund Society FSB increased its position in shares of Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock valued at $33,000 after purchasing an additional 587 shares during the period. Compass Planning Associates Inc acquired a new position in Moderna during the fourth quarter worth about $37,000. Venturi Wealth Management LLC grew its holdings in Moderna by 286.2% during the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock worth $37,000 after acquiring an additional 664 shares during the period. Crowley Wealth Management Inc. acquired a new stake in Moderna in the 4th quarter valued at about $41,000. Finally, MassMutual Private Wealth & Trust FSB lifted its holdings in Moderna by 58.2% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock valued at $44,000 after acquiring an additional 389 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on MRNA shares. Morgan Stanley lowered their price objective on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 15th. Barclays lowered Moderna from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $111.00 to $45.00 in a research note on Tuesday, February 18th. Berenberg Bank boosted their target price on Moderna from $33.00 to $42.00 and gave the stock a “hold” rating in a research report on Thursday, January 16th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $40.00 target price on shares of Moderna in a report on Tuesday, February 18th. Finally, Bank of America dropped their price target on Moderna from $41.00 to $34.00 and set an “underperform” rating on the stock in a research note on Tuesday, February 11th. Four investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $59.00.

Moderna Price Performance

Shares of MRNA stock opened at $28.35 on Tuesday. Moderna, Inc. has a fifty-two week low of $26.80 and a fifty-two week high of $170.47. The stock’s 50-day moving average is $34.60 and its two-hundred day moving average is $43.84. The firm has a market cap of $10.96 billion, a P/E ratio of -3.05 and a beta of 1.86.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.